MedTrace Logo

Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study

NCT01943383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21

Last updated 2018-05-31

No results posted yet for this study

Summary

Patients enrolled in this study will have completed one of the parent studies "Pharmacogenomic Evaluation of Antihypertensive Responses" (PEAR-1 or PEAR-2) evaluating how well their blood pressure was controlled by medication. Patients in the current study will provide a single tube of blood which will be used to create adult stem cells that can be converted into other cell types, like heart or vasculature. Patients will not be asked to return for any follow up visits.

Conditions

Interventions

GENETIC

iPSC

Single blood draw for the production of induced pluripotent stem cells.

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Julie A Johnson, PharmD · University of Florida

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01943383 on ClinicalTrials.gov